Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic
Antibodies · 19.11.2026 · 15 (6) · 110
DOI: 10.3390/antib15060110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 19.11.2026. Verfasst von Jacopo Olivieri und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anti-CD20 maintenance prolongs progression-free survival (PFS) in follicular lymphoma (FL) but sustains B-cell depletion and blunts vaccine responses. Methods: we conducted a retrospective study comparing two Italian centres that, during the COVID-19 pandemic, adopted opposite policies: Centre A continued maintenance; Centre B discouraged it.
Results
Among 62 consecutive patients completing first- or second-line induction in 2019–2022, maintenance was started in 47 (95% and 41% by centre; 92% and 27% among patients aged ≥70 years); patients not receiving it were older (79 vs. 66 years, p < 0.001). After a median follow-up of 70 months, crude 5-year PFS favoured maintenance (59% vs. 27%; hazard ratio [HR] 0.39), but the advantage shrank after adjustment for age (HR 0.72, 95% CI 0.30–1.72) or overlap propensity weighting (HR 0.60, 0.27–1.31); overall survival did not differ. The strong association between more than four cycles and survival (HR 0.22) faded at a 12-month landmark (HR 0.61, 0.19–1.95), consistent with immortal-time bias. All five COVID-19 deaths (10.6%) occurred in maintained patients, 2.0–3.7 months after the last dose and mostly without seroconversion, and none among the older patients without maintenance. Censoring these deaths brought the PFS benefit back within the range of randomised trials (weighted HR 0.41, 0.17–0.96).
Conclusions
In this small real-world cohort, COVID-19 mortality appears to have offset much of the expected gain from maintenance during the pandemic.
Zitieren
APA
Olivieri, J., Liotta, V., Ballerini, M., Lauzzana, P., Moratti, M., Petruzzellis, G., Pasquale, R., Plos, R., Lucchini, E., Ballotta, L., Turoldo, M., Patriarca, F., Zaja, F., & Fanin, R. (2026). Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic. Antibodies, 15(6), 110. https://doi.org/10.3390/antib15060110
Vancouver
Olivieri J, Liotta V, Ballerini M, Lauzzana P, Moratti M, Petruzzellis G, et al. Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic. Antibodies. 2026;15(6):110. doi:10.3390/antib15060110
BibTeX
@article{Olivieri2026,
author = {Olivieri, Jacopo and Liotta, Valeria and Ballerini, Mario and Lauzzana, Pietro and Moratti, Massimo and Petruzzellis, Giuseppe and Pasquale, Raffaella and Plos, Rosa and Lucchini, Elisa and Ballotta, Laura and Turoldo, Matteo and Patriarca, Francesca and Zaja, Francesco and Fanin, Renato},
title = {Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {6},
pages = {110},
doi = {10.3390/antib15060110}
}
EUVIMED